OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.
On July 8, 2020, contract development and manufacturing organization (CDMO) Vetter announced that it is further investing in additional fill/finish capacity with the purchase of a clinical manufacturing site located in Austria.
The production site was purchased along with existing inventory, including a vial-filling line and a freeze dryer for liquid and lyophilized products, in addition to material preparation and laboratory equipment. Vetter Development Service Rankweil plans to start-up operations at the newly acquired facility in the second half of 2021.
“With the additional site we will further support our capability for early clinical development in Phase I and Phase II. Over the coming months the facility will be evaluated and modified to the extensive Vetter quality and process standards in aseptic fill and finish for injection systems. Only an hour’s drive from Vetter’s headquarters in Ravensburg, Germany, the new site is well-positioned for a successful integration into our existing clinical operations,” said Thomas Otto, managing director, Vetter, in a company press release.
“An ever-growing number of pharmaceutical and biotech companies are seeking manufacturing partners who provide comprehensive clinical manufacturing resources as well as customized and product-specific support with their development strategy,” added Senator h.c. Udo J. Vetter, chairman of the company’s advisory board, in the press release. “The new site expands our European footprint and can be seen as counterpart to our existing US clinical manufacturing site near Chicago.”